SureNano Science Advances GLP-1 Therapy
SureNano Science has launched an FDA-aligned IND-enabling program for GEP-44, a GLP-1 therapy for obesity and diabetes. Preclinical data suggests it rivals market leaders as the company moves toward clinical trials. The market for such therapies exceeds $200 billion.
Topics
Developing
- 907d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 907d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 907d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 907d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Source Alpha
Source Bravo
Source Charlie
Source Delta
Source Echo
Source Foxtrot
Source Golf
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade